Meiogenix is a French biotech company that holds an exclusive and worldwide license for a technology that modulates the frequency of homologous recombination in eukaryotic cells. This technology facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties with commercial potential.
Total raised: $13M
Founded date: 2010
Investors 4
| Date | Name | Website |
| 21.07.2021 | Genoa Vent... | genoavc.co... |
| - | Agoranov | agoranov.c... |
| - | Kurma Part... | kurmapartn... |
| 30.08.2022 | Kevin M. M... | mcgovernce... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 14.12.2021 | Series A | $13M | - | globenewsw... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 19.08.2022 | Meet Jenny Rooke, founder and Managing Partner at Genoa Vent... | Genoa Ventures invests at the intersection of biology and technology Venture capital used to be a c... | vator.tv/n... |
| 16.12.2021 | Reddit is—finally—going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 14.12.2021 | Meiogenix Announces $13 Million Series A Financing Round Led... | Paris, France, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Meiogenix, an agriculture biotech company using the... | globenewsw... |
| 14.12.2021 | Meiogenix Announces $13 Million Series A Financing Round Led... | Paris, France, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Meiogenix, an agriculture biotech company using the... | marketscre... |